Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BAT2206 vs Stelara in Healthy Chinese Males
NCT04371185Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Aug 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAT2206 in psoriasis (3 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Peak Plasma Concentration and Area Under the Plasma Concentration versus Time Curve. Started Aug 2020; status: completed.
02
Drugs
BAT2206
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04371185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371185.